{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fher2-adcs-safety-and-tolerability-RNLUQdZr","width":444,"version":"1.0","type":"rich","title":"Uncovering Safety and Signposts to the Future: AEs With HER2-Targeted ADCs and Future Applications","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/2013a44b-8adb-45f8-a38b-1e07caeec944/100524-multitumor-her2-am-3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/043dd141-9788-4a08-bea3-52c45cedb50a\" height=\"200\" width=\"100%\" title=\"Uncovering Safety and Signposts to the Future: AEs With HER2-Targeted ADCs and Future Applications\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"This podcast explores the role of HER2-targeted antibody–drug conjugates (ADCs), evolving safety considerations, and future directions across genitourinary, gastrointestinal, and gynecologic cancers."}